In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
- Spiolto Improves Lung Function in Japanese COPD Patients against Spiriva in Trial: BI
May 8, 2018
- XLH Drug Crysvita Now Available in US: Kyowa Kirin/Ultragenyx
May 8, 2018
- FDA OKs Label Update for Takeda/Lundbeck’s Trintellix
May 8, 2018
- Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
- Kyowa Kirin to Focus on New Drugs in Europe, US to Achieve Midterm Targets: New President
May 7, 2018
- Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
- Daiichi Sankyo to Streamline Vaccine Business in April 2019, Setting Up New Manufacturing Company
May 7, 2018
- Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
- Daiichi Sankyo to Announce “Important Measures” to Shore Up Biz by 2nd Qtr Earnings
May 1, 2018
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
- Keytruda-Chemo Combo Filed for NSCLC without PD-L1 Cutoff
May 1, 2018
- Sumitomo Dainippon Slashes FY2017 Profit Outlook
April 27, 2018
- Boehringer Ingelheim Japan Sees 10% Dip in Pharma Sales as Micardis LOE Weighs
April 27, 2018
- Astellas Vows Intensive Investment in 6 Late-Stage Assets to Weather Patent Cliff: CEO
April 27, 2018
- Torii Calls Off PII Study of Menlo’s Pruritus Candidate
April 27, 2018
- Ono Files Metyrosine in Japan
April 27, 2018
- Chugai Seeks Japan OK for Hemlibra in Non-Inhibitor Carriers, New Dosing
April 27, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…